Amgen Stock Steadies Above $430 Amid Q2 Earnings Beat and Raised Guidance

Amgen stock has stabilized above $430 following its second-quarter earnings report for 2026. The biotech company's revenue reached $10.05 billion, a 9.5 percent increase from the same period last year and exceeding analyst expectations of $9.43 billion.

The strong performance was driven by broad-based growth across Amgen's portfolio and supported by operational leverage. Earnings per share came in at $6.29, which was $0.67 above the consensus estimate.

Amgen reaffirmed its guidance for 2026, indicating an expected earnings per share range of $22.30 to $23.50. This suggests continued double-digit growth and frames expectations for margins and cash generation over the rest of the year.

The company's stock price has shown significant appreciation in recent months, with a 34.82 percent year-to-date gain. The current price-to-earnings multiple is just under 19 times, using the mid-point of the guided range as the denominator.